BackBiomarin Pharmaceutical - Registered Shares Overview

Biomarin Pharmaceutical - Registered Shares Intangible Assets

Track Biomarin Pharmaceutical - Registered Shares's intangible assets ($4.9B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$4.88B
1936.29% YoYΔ $4.64B vs prior year quarter

Peer trimmed avg / median

Loading

Biomarin Pharmaceutical - Registered Shares Intangible Assets History

Loading

Biomarin Pharmaceutical - Registered Shares vs. peers: Intangible Assets Comparison

Loading

Biomarin Pharmaceutical - Registered Shares Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Biomarin Pharmaceutical - Registered Shares (BMRN) FAQ

Biomarin Pharmaceutical - Registered Shares's intangible assets stands at $4.9B as of June 2026. That compares with $240M in the prior-year period — up 1936.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Biomarin Pharmaceutical - Registered Shares reported $4.9B in intangible assets versus $240M a year earlier — a 1936.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $240M in the prior-year period — up 1936.3% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Biomarin Pharmaceutical - Registered Shares's intangible assets evolved across reporting periods, while the comparison chart places BMRN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Biomarin Pharmaceutical - Registered Shares's reading of $4.9B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.